PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30943275-1 2019 BACKGROUND: Based on non-clinical data, it is expected that azilsartan, an angiotensin II receptor blocker, will help improve insulin resistance in addition to its hypotensive action. azilsartan 60-70 insulin Homo sapiens 126-133 35350513-2 2022 The objective of this study was to investigate and compare the effect of azilsartan and telmisartan on insulin resistance and metabolic biomarkers in patients with both hypertension and type 2 diabetes mellitus. azilsartan 73-83 insulin Homo sapiens 103-110 30943275-2 2019 The present study is aimed to explore the effect of azilsartan compared to telmisartan on insulin sensitivity in hypertensive patients in the clinical setting. azilsartan 52-62 insulin Homo sapiens 90-97 28290827-5 2016 Several preclinical studies have shown the additional properties of azilsartan, including increase of insulin sensitivity, cardio- and nephron protection in obesity. azilsartan 68-78 insulin Homo sapiens 102-109 27731574-6 2016 Azilsartan"s very high affinity to and slow dissociation from the angiotensin 1 receptor (AT1R) along with its inverse agonistic properties make it a very good candidate for clinical effects beyond simple BP control, potentially counteracting cardiac hypertrophy, cardiac fibrosis and insulin resistance, together with improved reno-protection and atherosclerotic plaque stabilization. azilsartan 0-10 insulin Homo sapiens 285-292